Novos adjuvantes vacinais: importante ferramenta para imunoterapia da leishmaniose visceral

Nascimento, Leopoldo Fabrício Marçal do; Moura, Luana Dias de; Lima, Rebecca Tavares; Cruz, Maria do Socorro Pires e.
HU rev ; 44(3): 401-410, 2018.
Artículo en Portugués | LILACS | ID: biblio-1048110

Documentos relacionados

  1. Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination.
  2. Vaccine adjuvants: Tailoring innate recognition to send the right message.
  3. Vaccine adjuvants: mechanisms and platforms.
  4. Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.
  5. Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review.
  6. Detection of Nanoparticles' Ability to Stimulate Toll-Like Receptors Using HEK-Blue Reporter Cell Lines.
  7. The association between rLiHyp1 protein plus adjuvant and amphotericin B is an effective immunotherapy against visceral leishmaniasis in mice.
  8. Impelling TLR9: Road to perspective vaccine for visceral leishmaniasis.
  9. Recent advances in self-adjuvanting glycoconjugate vaccines.
  10. Therapeutic targeting of the innate immune system in domestic animals.